In this first of two podcasts, hear Dr Vibeke Strand discuss key information from ACR Convergence 2021, including the potential to intervene in patients who are at high risk for developing rheumatoid arthritis; whether vitamin D3 and n-3 fatty acids can prevent autoimmune disease; the Food and Drug Administration’s perspective on the safety of Janus kinase inhibitors; and results from a phase 3b/4 randomized safety study of tofacitinib vs tumor necrosis factor inhibitors. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.